

MAY 31 2005

Complete if Known

# SECOND INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

1

of

2

Application Number

10/516,613

Filing Date

December 3, 2004

First Named Inventor

Paolo Alberto Veronesi et al.

Examiner Name

Attorney Docket Number

019019-009

## U.S. PATENT DOCUMENTS

Examiner Initials	Document Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Issue/Publication Date (MM-DD-YYYY)
<i>[Signature]</i>	5,759,565		Azria et al.	06-02-1998
<i>[Signature]</i>	3,931,141		Wissmann et al.	01-06-1976

## FOREIGN PATENT DOCUMENTS

Examiner Initials	Document Number	Kind Code (if known)	Country	Date of Publication (MM-DD-YYYY)	STATUS						
					Translation	Partial Translation	Eng. Lang. Summary	Search Report	IPER	Abstract	Cited in Spec
<i>[Signature]</i>	99/59543	A1	WO	11-25-1999						X	X
<i>[Signature]</i>	0122036	A1	EP	10-17-1984						X	X
<i>[Signature]</i>	0094157	A1	EP	11-16-1983						X	X
<i>[Signature]</i>	0302772	A1	EP	02-08-1989						X	X
<i>[Signature]</i>	0468182	A1	EP	01-29-1992						X	X
<i>[Signature]</i>	2256445		DE	05-22-1974	X <sup>1</sup>						X
<i>[Signature]</i>	860717		BE	11-30-1977	X <sup>2</sup>						X
<i>[Signature]</i>	1539318		GB	01-31-1979							
<i>[Signature]</i>	55055120	A	JP	04-22-1980						X	X

## NON-PATENT LITERATURE DOCUMENTS

Examiner Initials	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
<i>[Signature]</i>	Nishihata et al., <i>J. Pharm. Pharmacol.</i> , 33, 334-335(1981), The Pharmaceutical Society of Great Britain, Pharmaceutical Press, London, GB.
<i>[Signature]</i>	Wigley et al., <i>Diabetes</i> , vol. 20, no. 8, 552-556,(1971), the American Diabetes Association, Alexandria, VA.
<i>[Signature]</i>	<i>Journal of the Diabetic Society</i> , Summary, 237 (1974), Japan Diabetes Society, Tokyo, JP.
<i>[Signature]</i>	Lemp et al., <i>Amer. J. Ophthalmol.</i> 105, 6 (1988), 670-673, Elsevier, Inc., New York, NY.
<i>[Signature]</i>	Bruynzeel et al., <i>Contact Dermatitis</i> , 17, 1 (1987), 41-42, Blackwell Munksgaard, Copenhagen, DK.
Examiner Signature	Date Considered
<i>[Signature]</i>	06/07

\*EXAMINER: Initial reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

<sup>1</sup>See English-language counterpart, Wissmann et al. U. S. Patent No. 3,931,141.

<sup>2</sup>See English-language counterpart, GB1539318.

MAY 31 2005

# **SECOND INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

2

of

2

Application Number

10/516,613

Filing Date

December 3, 2004

First Named Inventor

Paolo Alberto Veronesi et al.

Examiner Name

Attorney Docket Number

019019-009

## **NON-PATENT LITERATURE DOCUMENTS**

Examiner Initials	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
<i>[Signature]</i>	Fisher, <i>Cutis</i> , 39, 5(1987), 381-383, Quadrant HealthCom, Chatham, NJ.
<i>[Signature]</i>	Chevance et al., <i>Acta Otolaryng.</i> 70 (1970), 16-28, Taylor & Francis AB, Stockholm, SE.
<i>[Signature]</i>	<i>The Merck Index</i> , ed. Susan Budavari et al., twelfth edition (1996), entry no. 2148, p.350, Merck & Co., Inc., Whitehouse Station, NJ.
<i>[Signature]</i>	Dua et al., <i>International Journal of Pharmaceutics</i> , 147 (1997), 233-242, Elsevier BV, Amsterdam, NL.
<i>[Signature]</i>	Felber et al. <i>Experientia</i> 25, 11 (1969), 1195-1196, Birkhäuser Verlag, Basel, CH.
<i>[Signature]</i>	Gennser et al., <i>The Lancet</i> , 1, No. 7862 (1974), 865, Little, Brown and Company, Boston, MA.
<i>[Signature]</i>	Greenberg et al., <i>Antimicrobial Agents and Chemotherapy</i> , Vol. 14, No. 4 (1978), 596-600, American Society for Microbiology, Washington, D.C.
<i>[Signature]</i>	Bergquist et al., <i>The Lancet</i> , 2, No. 8136 (1979), 215-217, Little, Brown and Company, Boston, MA.
<i>[Signature]</i>	Pontiroli et al., <i>British Medical Journal</i> , Vol. 284, 6312 (1982), 303-306, BMJ Publishing Group, London, GB.
<i>[Signature]</i>	<i>Aerosols in Medicine</i> , ed. F. Morén et al. second, revised edition (1993), 346, Elsevier Science Publishers B.V., Amsterdam, NL.

Examiner Signature

Date Considered

06/07

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

<sup>1</sup>See English-language counterpart, Wissmann et al. U. S. Patent No. 3,931,141.

<sup>2</sup>See English-language counterpart, GB1539318.

~~DT05 Rec'd PCT/PTO 03 DEC 2004~~

**Complete known**

(use as many sheets as necessary)

1

019019-009

[illegible][illegible]

Examiner Initials	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.

06/05

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.